African cherry

The tree has dark, fissured bark, glossy leaves with finely toothed margins and small fruits that ripen from red to dark purple. It contributes food and forest structure across fragmented montane habitats.

Bark has local medicinal histories and is processed commercially into phytosterol-rich extracts used in products for urinary symptoms associated with benign prostatic enlargement. Evidence and authorisation apply to defined extracts, not unsupervised bark preparations.

Unsustainable ring-barking can kill trees, while heavy stripping reduces health and reproduction. CITES documentation, harvest inventory, strip dimensions, retained bark, recovery monitoring and export reconciliation are key assurance records.

Some standardised bark extracts have been clinically studied for urinary symptoms, with variable evidence quality and product composition. Symptoms can indicate conditions requiring diagnosis; botanical material should not replace medical evaluation.

Research has characterised phytosterols and other bark constituents and compared harvest practices. Conservation evidence consistently shows that harvest intensity and technique determine whether individual trees recover.

Responsible supply can support forest custodians and create incentives to retain mature trees. Core indicators include legal quota, tree inventory, post-harvest survival, regeneration, CITES reconciliation and payments at community level.

The species links local forest use to a high-value international market. Benefit-sharing, transparent pricing and community forest rights are therefore part of the provenance story, not optional narrative additions.